GlassScriptPhysician profile
Gregory D Schapiro
NPI 1619931383
$4,351.26
in general payments reported to CMS, 2019-2025
27 companies · $950 in 2025
The $950 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $815 · 2020: $155 · 2021: $137 · 2022: $619 · 2023: $763 · 2024: $913 · 2025: $950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,625.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,034.95 | 2019-2025 | Skyrizi, Rinvoq, Mavyret |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $581.98 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $350.84 | 2019-2025 | Stelara, Simponi, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $229.66 | 2019-2025 | Entyvio, Gattex |
| Celgene Corporation | $202.89 | 2022-2024 | Zeposia |
| Pfizer INC. | $103.91 | 2019-2025 | |
| Medtronic, INC. | $91.64 | 2024 | Interstim |
| Qol Medical, LLC | $90.97 | 2023-2025 | Sucraid |
| Gilead Sciences, INC. | $81.54 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $74.21 | 2022-2023 | Dificid |
| Madrigal Pharmaceuticals | $72.98 | 2025 | Rezdiffra |
| Allergan, INC. | $48.46 | 2019 | |
| Intercept Pharmaceuticals, INC. | $48.10 | 2019-2025 | Ocaliva |
| Aimmune Therapeutics, INC. | $43.89 | 2023-2025 | Zenpep |
| Ardelyx, INC. | $42.80 | 2023-2024 | Ibsrela |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $42.40 | 2022-2024 | Dupixent |
| Nestle Healthcare Nutrition INC. | $34.82 | 2022-2023 | |
| Daiichi Sankyo INC. | $24.64 | 2019 | |
| Genzyme Corporation | $20.42 | 2022 | |
| Braintree Laboratories, INC. | $19.32 | 2023 | Suflave |
| Digestive Care, INC. | $18.85 | 2022 | |
| Phathom Pharmaceuticals, INC. | $18.46 | 2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $16.97 | 2024 | |
| Ucb, INC. | $15.22 | 2019 | |
| Shire North American Group INC | $14.75 | 2019 | |
| Shionogi INC | $13.84 | 2019 | |
| Boston Scientific Corporation | $12.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Schapiro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.